Specific immunosuppression by immunotoxins containing daunomycin.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Science

• Publication date

  1986-01-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/SCIENCE.3484557PMID 3484557
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preparation of four daunomycin‐monoclonal antibody 79IT/36 conjugates with anti‐tumour activity

  1984cited by this paper
• Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates.

  1984cited by this paper
• The potential use of immunotoxins in transplantation, cancer therapy, and immunoregulation.

  1984cited by this paper
• SEROLOGICAL EQUIVALENCE OF ENDEMIC ZINGA VIRUS AND RIFT VALLEY FEVER VIRUS IN CENTRAL AFRICAN REPUBLIC

  1983cited by this paper
• Tolerance induction during ontogeny II. Distinct unresponsive states in immature mice question the generality of clonal abortion

  1983cited by this paper
• Selective abrogation of antigen-specific human B cell responses by antigen-ricin conjugates

  1982cited by this paper
• Monoclonal Antibody‐Ricin or Ricin A Chain Hybrids: Kinetic Analysis of Cell Killing for Tumor Therapy

  1982cited by this paper
• cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate.

  1981cited by this paper
• Directing toxins to cancer cells

  1981cited by this paper
• Tolerance induction during ontogeny. I. Presence of active suppression in mice rendered tolerant to human gamma-globulin in utero correlates with the breakdown of the tolerant state

  1979cited by this paper
• Daunomycin--immunoglobulin conjugates, uptake and activity in vitro.

  1978cited by this paper
• Thymus-independent antigens: the preparation of covalent, hapten-ficoll conjugates.

  1975cited by this paper
• The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities.

  1975cited by this paper
• Further improvements in the plaque technique for detecting single antibody-forming cells.

  1968cited by this paper
• ON PHYSICO-CHEMICAL INTERACTIONS BETWEEN DAUNOMYCIN AND NUCLEIC ACIDS.

  1965cited by this paper

• Anti-neoplastic cytotoxicity by complementary simultaneous selective “targeted” delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual-combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR]

  2018cites this paper
• Anti-neoplastic cytotoxicity by complementary simultaneous selective “targeted” delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual-combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR]

  2018cites this paper
• Gemcitabine‐(5′‐phosphoramidate)‐[anti‐IGF‐1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)

  2016cites this paper
• Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole

  2013cites this paper
• Development of Immunonconjugates for in Vivo Delivery: Cancer Diagnosis, Imaging, and Therapy

  2012cites this paper
• Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3.

  2012cites this paper
• Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic An

  2012cites this paper
• Synthesis of a Covalent Epirubicin-(C3-amide)-Anti-HER2/neu Immunochemotherapeutic Utilizing a UV-Photoactivated Anthracycline Intermediate

  2012cites this paper
• Reversibly crosslinked nanocarriers for on-demand drug delivery in cancer treatment.

  2012cites this paper
• Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma.

  2011cites this paper
• Environment-responsive multifunctional liposomes.

  2010cites this paper
• Liposomes

  2010cites this paper
• Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition

  2009cites this paper
• Journal of Neuroinflammation Cerebellar Purkinje Cells Incorporate Immunoglobulins and Immunotoxins in Vitro: Implications for Human Neurological Disease and Immunotherapeutics

  2009cites this paper
• Synthesis of poly(vinyl alcohol)-doxorubicin conjugates containing cis-aconityl acid-cleavable bond and its isomer dependent doxorubicin release.

  2008cites this paper
• Streptomycetes producing daunomycin and related compounds: Do we know enough about them after 25 years?

  2008cites this paper
• Effective drug-antibody targeting using a novel monoclonal antibody against the proliferative compartment of mammalian squamous carcinomas

  2005cites this paper
• Monoclonal antibody L6-daunomycin conjugates constructed to release free drug at the lower pH of tumor tissue

  2005cites this paper
• The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin

  2004cites this paper
• Monoclonal Antibodies as Magic Bullets

  2004cites this paper
• Abrogation of antibody responses in rats to murine monoclonal antibody 791T/36 by treatment with daunomycin-cis-aconityl-791T/36 conjugates

  2004cites this paper
• Immunotoxins: what is there in a scientific term?

  2004cites this paper
• Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect.

  2003cites this paper
• Monoclonal antibody drug immunoconjugates for targeted treatment of cancer

  2003cites this paper
• Isomer-dependent daunomycin release and in vitro antitumour effect of cis-aconityl-daunomycin.

  2003cites this paper
• NG2 precursor cells in neoplasia: Functional, histogenesis and therapeutic implications for malignant brain tumours

  2002cites this paper
• New strategies for polymer development in pharmaceutical science — a short review

  2001cites this paper
• Development and activities of the BR96-doxorubicin immunoconjugate.

  2001cites this paper
• Drug-polymer conjugates containing acid-cleavable bonds.

  1999cites this paper
• Human monoclonal antibodies: A tool for cancer detection in vivo

  1999cites this paper
• Mechanism of action and spectrum of cell lines sensitive to a doxorubicin–transferrin conjugate

  1997cites this paper
• Specific targeting of phototoxic haptenated liposomes to a hapten-specific B cell lymphoma.

  1996cites this paper
• Antibody-directed enzyme prodrug therapy (ADEPT).

  1996cites this paper
• Antibody-targeted polymer-bound drugs

  1995cites this paper
• Synthesis, controlled release properties and antitumour activity of alginate-cis-aconityl-daunomycin conjugates

  1995cites this paper
• Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs.

  1995cites this paper
• Site‐directed delivery of anthracyclines for treatment of cancer

  1995cites this paper
• Immunoconjugates and immunotoxins for therapy of carcinomas.

  1995cites this paper
• Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects.

  1994cites this paper
• Pharmacokinetics of succinylated proteins and dextran sulfate in mice : implications for hepatic targeting of protein drugs by direct succinylation via scavenger receptors

  1994cites this paper
• Chemoimmunoconjugates for the treatment of cancer.

  1994cites this paper
• Antigen “Suicide”: A Preliminary Study on the Induction of Specific Anti-Immunoglobulin Immunological Suppression in Vivo, Using Radiolabeled Immunoglobulin as “Lethal” Antigen

  1994cites this paper
• Conjugués d'agents bioactifs et d'alginate

  1993cites this paper
• Enhanced antitumor activity of daunomycin conjugated with antigastric cancer monoclonal antibody MGb2.

  1992cites this paper
• Molecular amplifiers: synthesis and functionalization of a poly(aminopropyl)dextran bearing a uniquely reactive terminus for univalent attachment to biomolecules.

  1992cites this paper
• Characterization of the Anti‐Cancer Activity of Transferrin‐Adriamycin Conjugates

  1992cites this paper
• Internalization of Monoclonal Antibodies Selected for Immunotoxin Activity Against Small-Cell Lung Cancer

  1992cites this paper
• Treatment of Acquired Autoimmune Myasthenia Gravis: a Topic Review

  1992cites this paper
• Xenogeneic monoclonal antibodies in the management of cancer: control of their in vivo immunogenicity and induction of specific unresponsiveness using an antibody-drug immunoconjugate.

  1991cites this paper
• Major histocompatibility complex antigens and murine islet allograft survival.

  1991cites this paper
• Antigen-specific immunodepression induced by doxorubicin-BSA conjugate in mice.

  1991cites this paper
• Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods.

  1991cites this paper
• Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers.

  1990cites this paper
• A new monoclonal antibody recognizing anthracyclinic molecule.

  1990cites this paper
• Immunoconjugate design: a predictive approach for coupling of daunomycin to monoclonal antibodies.

  1990cites this paper
• Electrophilic analogues of daunorubicin and doxorubicin.

  1990cites this paper
• Chemistry in a microenvironment of low pH, generated with the aid of an immobilized proteinase.

  1990cites this paper
• The linkage of cytotoxic drugs to monoclonal antibodies for the treatment of cancer.

  1990cites this paper
• Application of target-specific drug immunoconjugates to experimental bone marrow replacement therapy in mice.

  1990cites this paper
• Action of polymeric prodrugs based on N-(2-hydroxypropyl)meth- acrylamide copolymers. I. Suppression of the antibody response and proliferation of mouse splenocytes in vitro

  1989cites this paper
• Acid-sensitive latent inhibitors for proteolytic enzymes: synthesis and characterization.

  1989cites this paper
• The influence of syngeneic anti‐idiotypic antibody on the biodistribution of an anti‐tumour monoclonal antibody in balb/c mice

  1989cites this paper
• Proton-mediated liberation of aldophosphamide from a nontoxic prodrug: a strategy for tumor-selective activation of cytocidal drugs.

  1989cites this paper
• Monoclonal antibodies for treating cancer.

  1989cites this paper
• Tumor-inhibitory antibiotic uptake facilitated by leukoregulin: a new approach to drug delivery.

  1988cites this paper
• Pharmacokinetics and mechanism of action of a doxorubicin-monoclonal antibody 9.2.27 conjugate directed to a human melanoma proteoglycan.

  1988cites this paper
• Wound repair: the fibroblast and the inhibition of scar formation

  1988cites this paper
• Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations.

  1988cites this paper
• Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice.

  1988cites this paper
• IMMUNOSUPPRESSION OF GRAFT REJECTION WITH IDARUBICIN‐MONOCLONAL ANTIBODY CONJUGATES BY ELIMINATION OF T CELL SUBSETS IN VIVO

  1988cites this paper
• Enhancement of immunotoxin action: manipulation of the cellular routing of proteins.

  1988cites this paper
• Mechanisms of human CD5 modulation and capping induced by murine monoclonal antibody T101.

  1988cites this paper
• Chapter 16. Chemical Modification of Antibodies for Cancer Chemotherapy

  1988cites this paper
• Confusion about ‘immunotoxins’

  1988cites this paper
• 23 – Potential Use of Monoclonal Antibody–Drug Conjugates to Prevent Drug Resistance

  1988cites this paper
• Idiotype-specific T lymphocytes responsible for the selection of somatic variants of a B cell hybrid.

  1987cites this paper
• The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer

  1987cites this paper
• The design of cytotoxic-agent-antibody conjugates.

  1987cites this paper
• FACILITATION OF ALLOGENEIC BONE MARROW TRANSPLANTATION BY A T CELL–SPECIFIC IMMUNOTOXIN CONTAINING DAUNOMYCIN

  1987cites this paper
• Antigen-specific drug-targeting used to manipulate an immune response in vivo.

  1987cites this paper
• Monoclonal antibodies: potential applications to the treatment of cancer.

  1986cites this paper
• Radioimmunotherapy of malignancy using antibody targeted radionuclides.

  1986cites this paper
• The current status of monoclonal antibodies in the diagnosis and therapy of cancer.

  1986cites this paper